<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00024115</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068892</org_study_id>
    <secondary_id>NCI-01-C-0213</secondary_id>
    <secondary_id>NCI-5336</secondary_id>
    <nct_id>NCT00024115</nct_id>
    <nct_alias>NCT00021593</nct_alias>
  </id_info>
  <brief_title>BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Phase I Study of Recombinant BL22 Immunotoxin in Patients With CD22-Positive B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: The BL22 immunotoxin can locate tumor cells and kill them without harming normal&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of the BL22 immunotoxin in treating&#xD;
      patients who have non-Hodgkin's lymphoma or chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity and therapeutic efficacy of recombinant BL22 immunotoxin in&#xD;
           patients with CD22-positive B-cell non-Hodgkin's lymphoma or chronic lymphocytic&#xD;
           leukemia.&#xD;
&#xD;
        -  Determine the pharmacokinetics, including the terminal elimination serum half-life area&#xD;
           under the curve and volume of distribution, of recombinant BL22 immunotoxin in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the immunogenicity of recombinant BL22 immunotoxin in these patients.&#xD;
&#xD;
        -  Determine the effect of recombinant BL22 immunotoxin on various components of the&#xD;
           circulating cellular immune system in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive recombinant BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5.&#xD;
      Patients may be retreated at least every 20 days for up to 25 courses in the absence of&#xD;
      disease progression and sufficient neutralizing antibodies.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of recombinant BL22 immunotoxin until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BL22 immunotoxin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>antibody therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biological response modifier therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>immunotoxin therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed chronic lymphocytic leukemia or prolymphocytic leukemia:&#xD;
&#xD;
          -  Failed prior standard chemotherapy and treatment is medically indicated as evidenced&#xD;
             by the following:&#xD;
&#xD;
          -  Progressive disease-related symptoms&#xD;
&#xD;
          -  Progressive cytopenias due to marrow involvement&#xD;
&#xD;
          -  Progressive or painful splenomegaly or adenopathy&#xD;
&#xD;
          -  Rapidly increasing lymphocytosis&#xD;
&#xD;
          -  Autoimmune hemolytic anemia or thrombocytopenia&#xD;
&#xD;
          -  Increased frequency of infections OR&#xD;
&#xD;
          -  Confirmed CD22+ B-cell indolent non-Hodgkin's lymphoma&#xD;
&#xD;
          -  Stages II-IV that have failed at least 1 prior standard therapy and treatment is&#xD;
             medically indicated&#xD;
&#xD;
          -  No patients whose serum neutralizes BL22 or PE38 in tissue culture, due to antitoxin&#xD;
             or antimouse-IgG antibodies&#xD;
&#xD;
          -  No central nervous system disease requiring treatment&#xD;
&#xD;
          -  If the patient is non-leukemic, the absolute neutrophil count must be greater than&#xD;
             1,000/mm3 and the platelet count greater than 40,000/mm3&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  ALT and AST less than 5 times upper limit of normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Adequate renal function&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  Adequate pulmonary function&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Prior bone marrow transplantation allowed&#xD;
&#xD;
          -  At least 3 weeks since prior interferon for malignancy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior cytotoxic chemotherapy for malignancy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy for malignancy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior retinoids&#xD;
&#xD;
          -  At least 3 weeks since prior systemic therapy for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kreitman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2006</verification_date>
  <study_first_submitted>September 13, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage III grade I follicular small cleaved cell lymphoma</keyword>
  <keyword>stage III grade II follicular mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV grade I follicular small cleaved cell lymphoma</keyword>
  <keyword>stage IV grade II follicular mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade I follicular small cleaved cell lymphoma</keyword>
  <keyword>recurrent grade II follicular mixed cell lymphoma</keyword>
  <keyword>recurrent grade III follicular large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult diffuse small noncleaved cell/Burkitt's lymphoma</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>contiguous stage II grade I follicular small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II grade II follicular mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade I follicular small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade II follicular mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III diffuse small lymphocytic/marginal zone lymphoma</keyword>
  <keyword>contiguous stage II diffuse small lymphocytic/marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II diffuse small lymphocytic/marginal zone lymphoma</keyword>
  <keyword>stage IV diffuse small lymphocytic/marginal zone lymphoma</keyword>
  <keyword>recurrent diffuse small lymphocytic/marginal zone lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunotoxins</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

